Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V710 in Adult ESRD Patients on Hemodialysis
NCT00572910Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2008
- Primary completion
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, double-blind trial of V710 in Staphylococcus aureus infection (6 arms), sponsored by Merck & Co. Primary endpoints: Geometric Mean Fold-rise in 0657n-specific IgG Antibody Concentration at Day 56 and Number of Participants With Adverse Experiences (AE)/Serious Adverse Experiences (SAE). Started Aug 2008; status: completed.
02
Drugs
V710
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT00572910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00572910.